Ser1490
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus®
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser1490  -  LRP6 (human)

Site Information
AILNPPPsPAtERsH   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 456289

In vivo Characterization
Methods used to characterize site in vivo:
electrophoretic mobility shift ( 79 ) , flow cytometry ( 1 , 2 ) , immunoprecipitation ( 1 , 2 ) , mass spectrometry ( 3 , 6 , 10 , 13 , 15 , 16 , 17 , 18 , 20 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 ) , mutation of modification site ( 1 , 79 , 80 , 81 ) , phospho-antibody ( 1 , 2 , 5 , 7 , 8 , 9 , 22 , 68 , 78 , 80 ) , western blotting ( 1 , 2 , 5 , 8 , 9 , 22 , 68 , 78 )
Disease tissue studied:
brain cancer ( 7 ) , glioblastoma ( 7 ) , glioma ( 7 ) , breast cancer ( 10 ) , HER2 positive breast cancer ( 3 ) , luminal A breast cancer ( 3 ) , luminal B breast cancer ( 3 ) , breast cancer, triple negative ( 3 , 10 ) , cervical cancer ( 79 ) , cervical adenocarcinoma ( 79 ) , colorectal cancer ( 1 , 5 , 68 ) , colorectal carcinoma ( 1 , 68 ) , gastric cancer ( 16 , 20 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 42 , 45 , 46 , 47 , 49 , 50 , 51 , 55 , 56 , 57 , 60 , 61 , 64 , 66 , 69 , 70 , 71 , 72 ) , gastric carcinoma ( 20 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 42 , 45 , 46 , 47 , 49 , 50 , 51 , 55 , 56 , 57 , 60 , 61 , 64 , 66 , 69 , 70 , 71 , 72 ) , leukemia ( 77 ) , chronic myelogenous leukemia ( 77 ) , lung cancer ( 17 , 38 , 39 , 40 , 41 , 43 , 44 , 48 , 52 , 53 , 54 , 58 , 59 , 62 , 63 , 65 , 67 , 73 ) , non-small cell lung cancer ( 17 , 38 , 39 , 40 , 41 , 43 , 44 , 48 , 52 , 53 , 54 , 58 , 59 , 62 , 63 , 65 , 67 , 73 ) , non-small cell lung adenocarcinoma ( 40 , 43 , 44 , 48 , 53 , 58 , 59 , 62 , 63 , 65 , 67 , 73 ) , non-small cell squamous cell lung carcinoma ( 40 , 43 , 44 , 48 , 53 , 73 ) , melanoma skin cancer ( 6 )
Relevant cell line - cell type - tissue:
'stem, embryonic' ( 9 ) , 293 (epithelial) ( 1 , 2 , 78 , 79 ) , 293T (epithelial) ( 2 , 80 ) , A549 (pulmonary) ( 13 ) , breast ( 3 , 10 ) , GB2 ( 7 ) , H322 (pulmonary) ( 17 ) , HCC366 (pulmonary) ( 17 ) , HCC78 (pulmonary) ( 17 ) , HCT116 (intestinal) ( 1 ) , HeLa (cervical) ( 2 , 8 , 15 , 74 , 75 ) , HeLa S3 (cervical) ( 79 ) , HOP62 (pulmonary) ( 17 ) , Jurkat (T lymphocyte) ( 76 ) , K562 (erythroid) ( 15 , 77 ) , MEF (fibroblast) ( 80 ) , mesangial ( 22 ) , MKN-45 (gastric) ( 16 , 18 , 20 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 42 , 45 , 46 , 47 , 49 , 50 , 51 , 55 , 56 , 57 , 60 , 61 , 64 , 66 , 69 , 70 , 71 , 72 ) , NCI-H1703 (squamous) ( 18 , 40 , 43 , 44 , 48 , 53 , 73 ) , NCI-H3255 (pulmonary) ( 18 , 38 , 39 , 41 , 52 , 54 ) , NCI-H441 (pulmonary) ( 58 , 59 , 62 , 63 , 65 , 67 ) , SW480 (intestinal) ( 1 ) , T84 (intestinal) ( 68 ) , WM239A (epidermal) ( 6 )

Upstream Regulation
Regulatory protein:
C1QDC1 (human) ( 2 ) , CD44 (human) ( 8 ) , CDK14 (human) ( 2 ) , DVL1 (human) ( 78 ) , FZD2 (human) ( 78 ) , FZD4 (human) ( 78 ) , FZD5 (human) ( 78 ) , PI4K2A (human) ( 78 ) , PIP5K1A (human) ( 78 ) , PIP5K1B (human) ( 78 ) , WNT3 (human) ( 9 ) , WNT3A (human) ( 7 , 80 ) , WNT9B (human) ( 9 )
Putative in vivo kinases:
CDK14 (human) ( 2 ) , ERK1 (human) ( 19 ) , ERK2 (human) ( 19 ) , GSK3B (human) ( 79 , 80 )
Kinases, in vitro:
GSK3B (human) ( 80 )
Treatments:
CTGF ( 22 ) , FGF2 ( 9 , 19 ) , IFN-gamma ( 68 ) , PI(4,5)P2 ( 78 ) , siRNA ( 78 ) , TNF ( 68 ) , TPO ( 5 ) , U0126 ( 9 ) , Wnt3a ( 2 , 78 , 79 )

Downstream Regulation
Effects of modification on LRP6:
molecular association, regulation ( 7 , 79 , 81 ) , phosphorylation ( 80 )
Effects of modification on biological processes:
cell cycle regulation ( 2 ) , transcription, altered ( 79 )
Induce interaction with:
axin 1 (human) ( 79 , 81 ) , caveolin-1 (human) ( 79 )

References 

1

Liang J, et al. (2017) miR-27a-3p targeting RXRα promotes colorectal cancer progression by activating Wnt/β-catenin pathway. Oncotarget 8, 82991-83008
29137318   Curated Info

2

Wang X, et al. (2016) Activation/Proliferation-associated Protein 2 (Caprin-2) Positively Regulates CDK14/Cyclin Y-mediated Lipoprotein Receptor-related Protein 5 and 6 (LRP5/6) Constitutive Phosphorylation. J Biol Chem 291, 26427-26434
27821587   Curated Info

3

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

4

Lemieux E, et al. (2015) Oncogenic KRAS signalling promotes the Wnt/β-catenin pathway through LRP6 in colorectal cancer. Oncogene 34, 4914-27
25500543   Curated Info

5

Wu Z, et al. (2015) TPO-Induced Metabolic Reprogramming Drives Liver Metastasis of Colorectal Cancer CD110+ Tumor-Initiating Cells. Cell Stem Cell 17, 47-59
26140605   Curated Info

6

Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615
25850435   Curated Info

7

Koyama-Nasu R, et al. (2015) Thr160 of Axin1 is critical for the formation and function of the β-catenin destruction complex. Biochem Biophys Res Commun 459, 411-5
25735981   Curated Info

8

Schmitt M, et al. (2015) CD44 functions in Wnt signaling by regulating LRP6 localization and activation. Cell Death Differ 22, 677-89
25301071   Curated Info

9

Lee CT, et al. (2015) Functional consequences of 17q21.31/WNT3-WNT9B amplification in hPSCs with respect to neural differentiation. Cell Rep 10, 616-32
25640183   Curated Info

10

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

11

Li S, et al. (2014) Phosphorylation of cyclin Y by CDK14 induces its ubiquitination and degradation. FEBS Lett 588, 1989-96
24794231   Curated Info

12

Vinyoles M, et al. (2014) Multivesicular GSK3 sequestration upon Wnt signaling is controlled by p120-catenin/cadherin interaction with LRP5/6. Mol Cell 53, 444-57
24412065   Curated Info

13

Kim JY, et al. (2013) Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells. Proc Natl Acad Sci U S A 110, 12414-9
23836654   Curated Info

14

Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21
23312004   Curated Info

15

Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71
23186163   Curated Info

16

Rikova K (2012) CST Curation Set: 16137; Year: 2012; Biosample/Treatment: cell line, MKN45/crizotinib; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine (P-Tyr-1000) MultiMab(TM) Rabbit mAb mix Cat#: 8954
Curated Info

17

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

18

Stokes MP, et al. (2012) PTMScan Direct: Identification and Quantification of Peptides from Critical Signaling Proteins by Immunoaffinity Enrichment Coupled with LC-MS/MS. Mol Cell Proteomics 11, 187-201
22322096   Curated Info

19

Krejci P, et al. (2012) Receptor Tyrosine Kinases Activate Canonical WNT/β-Catenin Signaling via MAP Kinase/LRP6 Pathway and Direct β-Catenin Phosphorylation. PLoS One 7, e35826
22558232   Curated Info

20

Possemato A (2011) CST Curation Set: 11925; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

21

Tanneberger K, et al. (2011) Amer1/WTX couples Wnt-induced formation of PtdIns(4,5)P2 to LRP6 phosphorylation. EMBO J 30, 1433-43
21304492   Curated Info

22

Rooney B, et al. (2011) CTGF/CCN2 activates canonical Wnt signalling in mesangial cells through LRP6: implications for the pathogenesis of diabetic nephropathy. FEBS Lett 585, 531-8
21237163   Curated Info

23

Macdonald BT, Semenov MV, Huang H, He X (2011) Dissecting Molecular Differences between Wnt Coreceptors LRP5 and LRP6. PLoS One 6, e23537
21887268   Curated Info

24

Moritz A (2010) CST Curation Set: 10603; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

25

Moritz A (2010) CST Curation Set: 10611; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

26

Moritz A (2010) CST Curation Set: 10617; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

27

Moritz A (2010) CST Curation Set: 10606; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

28

Moritz A (2010) CST Curation Set: 10616; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

29

Moritz A (2010) CST Curation Set: 10602; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

30

Moritz A (2010) CST Curation Set: 10609; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

31

Moritz A (2010) CST Curation Set: 10604; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

32

Moritz A (2010) CST Curation Set: 10607; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

33

Moritz A (2010) CST Curation Set: 10610; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

34

Moritz A (2010) CST Curation Set: 10605; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

35

Moritz A (2010) CST Curation Set: 10608; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

36

Moritz A (2010) CST Curation Set: 10612; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

37

Moritz A (2010) CST Curation Set: 10601; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

38

Moritz A (2010) CST Curation Set: 10599; Year: 2010; Biosample/Treatment: cell line, NCI-H3255/DMSO; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

39

Moritz A (2010) CST Curation Set: 10597; Year: 2010; Biosample/Treatment: cell line, NCI-H3255/Iressa; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

40

Moritz A (2010) CST Curation Set: 10594; Year: 2010; Biosample/Treatment: cell line, NCI-H1703/Gleevec; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

41

Moritz A (2010) CST Curation Set: 10598; Year: 2010; Biosample/Treatment: cell line, NCI-H3255/Su11274; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

42

Moritz A (2010) CST Curation Set: 10600; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

43

Moritz A (2010) CST Curation Set: 10595; Year: 2010; Biosample/Treatment: cell line, NCI-H1703/Su11274; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

44

Moritz A (2010) CST Curation Set: 10596; Year: 2010; Biosample/Treatment: cell line, NCI-H1703/DMSO; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

45

Moritz A (2010) CST Curation Set: 10233; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

46

Moritz A (2010) CST Curation Set: 10238; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

47

Moritz A (2010) CST Curation Set: 10235; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

48

Moritz A (2010) CST Curation Set: 10240; Year: 2010; Biosample/Treatment: cell line, NCI-H1703/DMSO; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

49

Moritz A (2010) CST Curation Set: 10232; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

50

Moritz A (2010) CST Curation Set: 10237; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

51

Moritz A (2010) CST Curation Set: 10234; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

52

Moritz A (2010) CST Curation Set: 10241; Year: 2010; Biosample/Treatment: cell line, NCI-H3255/Iressa; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

53

Moritz A (2010) CST Curation Set: 10239; Year: 2010; Biosample/Treatment: cell line, NCI-H1703/Gleevec; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

54

Moritz A (2010) CST Curation Set: 10242; Year: 2010; Biosample/Treatment: cell line, NCI-H3255/DMSO; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

55

Moritz A (2010) CST Curation Set: 10236; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

56

Moritz A (2010) CST Curation Set: 10231; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

57

Moritz A (2010) CST Curation Set: 10243; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

58

Moritz A (2010) CST Curation Set: 9985; Year: 2010; Biosample/Treatment: cell line, NCI-H441/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

59

Moritz A (2010) CST Curation Set: 9984; Year: 2010; Biosample/Treatment: cell line, NCI-H441/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

60

Moritz A (2010) CST Curation Set: 10021; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

61

Moritz A (2010) CST Curation Set: 10020; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

62

Moritz A (2010) CST Curation Set: 9983; Year: 2010; Biosample/Treatment: cell line, NCI-H441/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

63

Moritz A (2010) CST Curation Set: 9986; Year: 2010; Biosample/Treatment: cell line, NCI-H441/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

64

Moritz A (2010) CST Curation Set: 10022; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

65

Moritz A (2010) CST Curation Set: 9980; Year: 2010; Biosample/Treatment: cell line, NCI-H441/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

66

Moritz A (2010) CST Curation Set: 10023; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

67

Moritz A (2010) CST Curation Set: 9987; Year: 2010; Biosample/Treatment: cell line, NCI-H441/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

68

Nava P, et al. (2010) Interferon-gamma regulates intestinal epithelial homeostasis through converging beta-catenin signaling pathways. Immunity 32, 392-402
20303298   Curated Info

69

Moritz A (2010) CST Curation Set: 9374; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

70

Moritz A (2010) CST Curation Set: 9373; Year: 2010; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

71

Moritz A (2010) CST Curation Set: 9279; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO &'||' Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

72

Moritz A (2010) CST Curation Set: 9234; Year: 2010; Biosample/Treatment: cell line, MKN-45/calyculin_A & pervanadate; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

73

Moritz A (2010) CST Curation Set: 9240; Year: 2010; Biosample/Treatment: cell line, NCI-H1703/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

74

Moritz A (2010) CST Curation Set: 9237; Year: 2010; Biosample/Treatment: cell line, HeLa/nocodazole; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

75

Moritz A (2010) CST Curation Set: 9243; Year: 2010; Biosample/Treatment: cell line, HeLa/UV; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

76

Moritz A (2010) CST Curation Set: 8838; Year: 2010; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

77

Moritz A (2010) CST Curation Set: 8837; Year: 2010; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

78

Pan W, et al. (2008) Wnt3a-mediated formation of phosphatidylinositol 4,5-bisphosphate regulates LRP6 phosphorylation. Science 321, 1350-3
18772438   Curated Info

79

Yamamoto H, Komekado H, Kikuchi A (2006) Caveolin is necessary for Wnt-3a-dependent internalization of LRP6 and accumulation of beta-catenin. Dev Cell 11, 213-23
16890161   Curated Info

80

Zeng X, et al. (2005) A dual-kinase mechanism for Wnt co-receptor phosphorylation and activation. Nature 438, 873-7
16341017   Curated Info

81

Tamai K, et al. (2004) A mechanism for Wnt coreceptor activation. Mol Cell 13, 149-56
14731402   Curated Info